Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.41 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070228 | 0.89 | PARP10 (0.47) | PARP10PARP4CA2CA1PARP1 | |
| SCHEMBL16897591 | 0.83 | OPRM1 (0.47) | PDE4APDE4BPDE4CPDE4DKCNA3 | |
| SCHEMBL15348097 | 0.82 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DKCNA3 | |
| SCHEMBL16287573 | 0.82 | KCNA3 (0.48) | PDE4APDE4BPDE4CPDE4DKCNA3 | |
| SCHEMBL11047897 | 0.82 | OPRM1 (0.47) | PDE4APDE4BPDE4CPDE4DKCNA3 | |
| SCHEMBL5765569 | 0.81 | MEN1 (0.50) | KCNA3KMT2AHSD11B1MEN1OPRM1 | |
| SCHEMBL195327 | 0.78 | THRB (0.44) | PDE4APDE4BPDE4CPDE4DKCNA3 | |
| SCHEMBL1018912 | 0.74 | POLB (0.49) | CA2CA1KCNA3KMT2AALDH1A1 | |
| SCHEMBL613788 | 0.74 | PARP10 (0.40) | PARP10PARP4CA2CA1PARP1 | |
| SCHEMBL16137494 | 0.74 | MEN1 (0.47) | KCNA3KMT2AHSD11B1MEN1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039474-B2 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-1833791-B1 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20090270414-A1 | 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-1833791-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006070325-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270414-A1 | 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, CRHR2, GRK2 | PDE4A 680/4885PDE4B 486/4885PDE4C 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.